On behalf of the Board of Cambium Bio Limited (ASX: CMB), I am pleased to invite you to the General Meeting of Cambium Bio Limited. This meeting will be held in person at the offices of the Company located at 16 Goodhope St Paddington NSW 2021 on Tuesday 4th March 2025 at 11:00am (Sydney time).
The Company’s General Meeting will be held in person.
A copy of the Notice of Meeting was released to the ASX today.
In accordance with Part 1.2AA of the Corporations Act 2001 (Cth), the Company will not be dispatching physical copies of the Notice of Meeting and instead a copy of the Notice of Meeting will be available to view online and download from the Company’s website https://www.cambium.bio/Investors-and-Media
The items of business to be conducted at the General Meeting are set out in the Notice of Meeting as the following Resolutions:
Resolution 1: Approval to issue Shares – Part 3 Placement –Sebastian Tseng and Zheng Yang Biomedical Technology Co., Ltd
Resolution 2: Approval of issue of Options and Shares under Part 3 Placement to Director – Dr Chandra Bala
Resolution 3: Approval of issue Shares under Part 3 Placement to Director – Edmund Waller
Resolution 4: Approval of issue Shares under Part 3 Placement to Director – Terence Walts
The Notice of Meeting contains explanatory information regarding all items of business, the Independent Expert’s Report in Annexure A for Resolution 1, and a Proxy Form.
The Board recommends that shareholders vote in favour of all items of business.
A Proxy Form in relation to the General Meeting is included with this letter. Voting on the resolutions at the General Meeting is important and Shareholders who are unable to attend the General Meeting in person are encouraged to exercise their voting rights by completing and returning the enclosed Proxy Form. Please refer to the full Notice of Meeting for further important information.
Should any shareholder have any queries regarding their shareholding, or in respect of the Company’s GM, please contact Cambium Bio’s share registry, MUFG Corporate Markets by phoning 1300 554 474 (within Australia) or +61 1300 554 474 (for shareholders located overseas).
You can also update your communication preferences to ensure you receive all future communication from the Company electronically, by updating your details online via https://au.investorcentre.mpms.mufg.com
The Board of Cambium Bio looks forward to welcoming you to the Company’s General Meeting.